Navigation Links
Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
Date:8/2/2009

STAMFORD, Conn. and PT. RICHMOND, Calif., Aug. 2 /PRNewswire-FirstCall/ -- Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced entry into an exclusive license and collaboration agreement to commercialize Intermezzo((R)) (zolpidem tartrate sublingual tablet) in the United States. If approved by the U.S. Food and Drug Administration (FDA), Intermezzo((R)) has the potential to be the first prescription sleep aid specifically approved for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. The FDA has established October 30, 2009 as the Prescription Drug User Fee Act (PDUFA) action date for the Intermezzo((R)) New Drug Application (NDA).

In the agreement announced today, Transcept has granted Purdue and a Purdue associated company an exclusive license to market, sell and distribute Intermezzo((R) )in the United States and the right to negotiate for the commercialization of the product in Canada and Mexico. Transcept has retained an option to co-promote Intermezzo((R) )to psychiatrists in the United States and has retained rights to commercialize Intermezzo((R)) in the rest of the world.

Under the terms of the agreement, Purdue will pay Transcept near-term milestones that include an upfront cash payment of $25 million and an additional payment of up to $30 million based upon the timing of an FDA approval of Intermezzo((R)), which approval and payment are subject to review and acceptance by Purdue. Transcept is eligible to receive up to an additional $90 million upon reaching future milestones related to achievement of intellectual property and U.S. net sales targets.

Purdue will pay double-digit royalties to Transce
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.; Purdue Pharmaceutical Products L.P.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Purdue creating wireless sensors to monitor bearings in jet engines
2. Purdue leads center to simulate behavior of micro-electromechanical systems
3. Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc.
4. Purdue researcher invents molecule that stops SARS
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...vember24/PRNewswire-FirstCall/--deCODE,genetics,In...ts,"firstday"motionsbytheU.S.BankruptcyCourtforthe...stweekfiledavoluntarypetitionfor,reliefunderChapte...cyCourt. , TheordersissuedbytheBankruptcyCour...ingtheChapter11proceedings.Inparticular,the,compan...
(Date:11/24/2009)...swire/--BlueMarbleEnergyCorp.announcedtodaythatthe...)wererecentlyawarded$2millionbyWashingtonState,sCo.../publicpartnershiptoconstructthestate,sfirstspecia... "Thisinvestmentwillsignificantlyspeedthedevelopme...County,"saidBlueMarbleEnergyCEOKellyOgilvie."Weare...
(Date:11/24/2009)...Newswire-FirstCall/--Shireplc(LSE:SHP,NASDAQ: SHP...day,announcedthatithassubmittedaMAAtotheEuropeanMe...ymereplacementtherapyindevelopment,forthetreatment...icationforvelaglucerasealfathathasbeensubmitted,wi..., Basedonaglobalsupplyshortageofthecurrentlya...
(Date:11/24/2009)...ogram Connects Customers with Partners Validated t...enotek Products , Ottawa,...leading provider of products for biological sample...announced its new global partner program. The prog...k,s partner community and is designed to help part...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
...#946; -lactamases are either plasmid or chromosoma...6; -lactam antibiotics. The majority of β -la...active site enzymes. One successful approach to co...is the use of β -lactamase inhibitors, such a...actam antibiotic 4 . , There is also a small gro...
..., , Molecular Devices Corporation,...says for proteolytic activity typically use synthe.... Enzyme selectivity is obtained by choosing a pep... site of a particular enzyme. The chromophore or f...site and enzymatic activity is detected by the inc...
..., Martin Boissonneault, Esther Tremblay, Benoit Ho... Recent advances in combinatorial chemistry a...increase in both the number of compounds and poten...pment of automated liquid handling and microplate ...creased throughput. Concomitantly, the introductio...
Other Biology Technology:A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 2A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 3A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 4A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 5A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 6Fluorometric Protease Assays in the SpectraMax Gemini Microplate Spectrofluorometer: Example Using Caspase3 (MaxLine Application Note #35) 2Fluorometric Protease Assays in the SpectraMax Gemini Microplate Spectrofluorometer: Example Using Caspase3 (MaxLine Application Note #35) 3Fluorometric Protease Assays in the SpectraMax Gemini Microplate Spectrofluorometer: Example Using Caspase3 (MaxLine Application Note #35) 4Fluorometric Protease Assays in the SpectraMax Gemini Microplate Spectrofluorometer: Example Using Caspase3 (MaxLine Application Note #35) 5Fluorometric Protease Assays in the SpectraMax Gemini Microplate Spectrofluorometer: Example Using Caspase3 (MaxLine Application Note #35) 6Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets. 2Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets. 3Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets. 4Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets. 5
(Date:11/23/2009)...D.C. The community-associated strain of the deadl...tant to most common antibioticsposes a far greater... its way into hospitals, according to a study in t... . , The new threat is easily picked up in fitn...has increased the overall burden of MRSA within ho...
(Date:11/23/2009)...CT Current research suggests that a common oral b...elated report by Nichols et al, "Unique Lipids fro...f TLR2 Ligands Capable of Enhancing Autoimmunity,"...an Journal of Pathology . , Multiple sclerosis (... brain and spinal cord, affects nearly 1 in 700 pe...
(Date:11/23/2009)...AM, Ala. A new study by University of Alabama at ...index (BMI) and co-existing medical conditions (co...observed among African-Americans compared to Cauca...lished online Nov. 23 in Cancer , a journal of th...es that although BMI and co-morbidity are independ...
Breaking Biology News(10 mins):New study finds MRSA on the rise in hospital outpatients 2Factors from common human bacteria may trigger multiple sclerosis 2Racial disparity in colon cancer survival not easily explained, UAB researchers say 2Battered Womens Ills Go Beyond Bruises 59314 1Battered Womens Ills Go Beyond Bruises 59314 2Gene mingling increases sudden death risk 10325 1Gene mingling increases sudden death risk 10325 2Gene mingling increases sudden death risk 10325 3With Hormone Therapy Tender Breasts May Signal Cancer Risk 59307 1With Hormone Therapy Tender Breasts May Signal Cancer Risk 59307 2With Hormone Therapy Tender Breasts May Signal Cancer Risk 59307 3
...e and Gene Therapy Institute (VGTI) at Oregon Heal...certain white blood cells literally eat virus-infe...ic level. The research not only helps provide a cl...t also offers hope of a new method for gauging vac...he current edition of the journal Nature Medicine....
...eurons may have been a key factor in why the human...latives. In a study comparing the genomes of human...chers at the U.S. Department of Energy,s Lawrence ...int Genome Institute (JGI) found a strikingly high...at appear to regulate genes involved in nerve cell...
...of the time, they are nothing but a cosmetic nuisa...s called melanocytes start dividing abnormally to ... About one in 65 Americans born this year will be...r lifetime. , Scientists know that 30 percent of ...ercent of moles contain cancer-causing mutations. ...
Other Biology News:OHSU researchers demonstrate how white blood cells cannibalize virus-infected cells 2Neuron cell stickiness may hold key to evolution of the human brain 2Neuron cell stickiness may hold key to evolution of the human brain 3Neuron cell stickiness may hold key to evolution of the human brain 4Why don't all moles progress to melanoma? 2Why don't all moles progress to melanoma? 3
... P is the latest entry in the Biomek line. With a...tional accuracy and increased robustness, it can m...n be configured with either one or two pipetting p... sets the standard for flexible laboratory soluti...
Costar 96-Well Flat-Bottom EIA Plates, polystyrene, 100 from Bio-Rad
...DR1 Shift Assay provides a convenient method to pr... transport of MDR1 substrates. Thus, the kit may b...cules act as transport substrates for MDR1. Becaus...sence of MDR1 substrates, the MDR1 Shift Assay can...
Polaroid Wide and Long Electrophoresis Hood from Bio-Rad
Biology Products: